From Natural Limonoids to a Rationally Designed Derivative: Facilitating the Study of Anti‐Adenocarcinoma Potential and Mechanisms Through Solubility Enhancement
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Juan Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science, Guangdong Pharmaceutical University, Guangzhou, China. Hauptthemen laut MEDLINE: Limonins, Drug Design, Adenocarcinoma, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Yunfu Traditional Chinese Medicine (Southern Medicine) Innovationn Team Project, Research group of functional foods development for specific populations, Special project in key areas of ordinary colleges and universities in Guangdong Province.
Abstract (Originalsprache)
Natural limonoids, exemplified by limonin from lemon seeds, exhibit promising antitumor activity but are hindered by poor aqueous solubility, which critically limits their bioavailability and cellular engagement. To address this, a rational structure‐based design was employed, focusing on the under‐explored C‐7 position. Methoxyamination of limonin yielded a novel derivative, limonin‐7‐methoxime. Comprehensive ¹H and ¹³C NMR spectroscopy confirmed its structure, and the modification markedly improved aqueous solubility. Cytotoxicity assessment across three human adenocarcinoma cell lines (MCF‐7, HT‐29, LNCaP) showed that both limonin‐7‐methoxime and the natural analog obakunone exerted measurable, albeit moderate, activity. They exhibited the strongest effect against LNCaP prostate cancer cells, with IC 50 values of 249.35 and 236.15 μM, respectively. Mechanistic studies indicated that both compounds were associated with cell cycle arrest and the activation of caspase‐3‐mediated apoptosis in LNCaP cells. Collectively, this work validates C‐7 functionalization as an effective strategy to enhance the drug‐like properties of limonoids. It delivers a structurally optimized lead compound and provides a foundation for further development aimed at improving its antitumor potency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food Science, Guangdong Pharmaceutical University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong Pharmaceutical University, Guangzhou, China.
- College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangzhou, China.
ORCID-Profile: Juan Guo
Förderung
- National Natural Science Foundation of China
- Yunfu Traditional Chinese Medicine (Southern Medicine) Innovationn Team Project, Research group of functional foods development for specific populations
- Special project in key areas of ordinary colleges and universities in Guangdong Province
- Heyuan City Science and Technology Plan Project
- Guangdong MEPP Fund
Zitieren
APA
Guo, J., Luo, X., Chen, Z., Zhang, X., Li, D., Yu, H., Gong, Y., Bi, Y., & Li, H. (2026). From Natural Limonoids to a Rationally Designed Derivative: Facilitating the Study of Anti‐Adenocarcinoma Potential and Mechanisms Through Solubility Enhancement. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70210
Vancouver
Guo J, Luo X, Chen Z, Zhang X, Li D, Yu H, et al. From Natural Limonoids to a Rationally Designed Derivative: Facilitating the Study of Anti‐Adenocarcinoma Potential and Mechanisms Through Solubility Enhancement. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70210
BibTeX
@article{Guo2026,
author = {Guo, Juan and Luo, Xinyi and Chen, Zexin and Zhang, Xinlai and Li, Dongmei and Yu, Hong and Gong, Yushi and Bi, Yongguang and Li, Huilin},
title = {From Natural Limonoids to a Rationally Designed Derivative: Facilitating the Study of Anti‐Adenocarcinoma Potential and Mechanisms Through Solubility Enhancement},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70210}
}
EUVIMED